Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Alane Barnes sold 150,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the transaction, the insider owned 400,703 shares in the company, valued at approximately $3,666,432.45. This trade represents a 27.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

BioCryst Pharmaceuticals Trading Down 1.1%

BCRX stock opened at $9.70 on Friday. The firm has a market cap of $2.43 billion, a PE ratio of 8.08 and a beta of 0.74. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.31. The company has a fifty day simple moving average of $7.50 and a 200 day simple moving average of $7.44.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The firm had revenue of $163.28 million for the quarter, compared to the consensus estimate of $151.32 million. During the same period in the prior year, the business posted ($0.13) earnings per share. The business’s quarterly revenue was up 209.1% on a year-over-year basis. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Royal Bank Of Canada cut their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Evercore began coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price target on the stock. Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. Finally, HC Wainwright boosted their price objective on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.64.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors have recently modified their holdings of BCRX. Larson Financial Group LLC lifted its position in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares during the period. Focus Partners Wealth bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $77,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares during the period. Envestnet Portfolio Solutions Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $81,000. Finally, Farther Finance Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 8,109 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.